Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling [version 1; peer review: 3 approved]

Lynlee L Lin, Tarl W Prow, Anthony P Raphael, Robert L Harrold III, Clare A Primiero, Alexander B Ansaldo, H Peter Soyer

Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, QLD 4012, Australia

Abstract

We describe the development of a sub-millimetre skin punch biopsy device for painless and suture-free skin sampling for molecular diagnosis and research. Conventional skin punch biopsies range from 2-4 mm in diameter. Local anaesthesia is required and sutures are usually used to close the wound. Our microbiopsy is 0.50 mm wide and 0.20 mm thick. The microbiopsy device is fabricated from three stacked medical grade stainless steel plates tapered to a point and contains a chamber within the centre plate to collect the skin sample. We observed that the application of this device resulted in a 0.21 ± 0.04 mm wide puncture site in volunteer skin using reflectance confocal microscopy. Histological sections from microbiopsied skin revealed 0.22 ± 0.12 mm wide and 0.26 ± 0.09 mm deep puncture sites. Longitudinal observation in microbiopsied volunteers showed that the wound closed within 1 day and was not visible after 7 days. Reflectance confocal microscope images from these same sites showed the formation of a tiny crust that resolved by 3 weeks and was completely undetectable by the naked eye. The design parameters of the device were optimised for molecular analysis using sampled DNA mass as the primary end point in volunteer studies. Finally, total RNA was characterized. The optimised device extracted 5.9 ± 3.4 ng DNA and 9.0 ± 10.1 ng RNA. We foresee that minimally invasive molecular sampling will play an increasingly significant role in diagnostic dermatology and skin research.

Keywords

skin punch biopsy; microbiopsy; neoplasm, diagnostic tool
Introduction
Skin biopsy is one of the most essential techniques in dermatology for accurate diagnosis of neoplastic or inflammatory skin diseases through histopathological assessment. This technique is performed under local anaesthetic by trained medical personnel, normally a dermatologist, to remove a skin sample 2–4 mm in diameter (Figure 1) that is then preferably sent to a dermatopathologist for histopathological diagnosis. Pathological examination using skin biopsies often complements and/or confirms diagnosis of common neoplastic or inflammatory skin diseases. This technique is usually performed using a punch biopsy tool or a scalpel. The wound is then either sutured or left to heal.

An excisional biopsy, a common alternative in neoplastic skin conditions, is performed when the entire tumour is needed for histopathological examination, or when melanoma is suspected. This depends on the size and location of the lesion and can be performed using a larger 4–6 mm diameter punch biopsy, a deep shave biopsy, or with a fusiform excision. These biopsy techniques coupled with histopathology are able to provide accurate diagnosis of the disease occurrence and progression, however the downsides of these techniques are that they require local anaesthesia and sutures in addition to the time required to carry out the procedure. Furthermore, samples are generally fixed with formalin that hinders molecular analysis. Molecular fingerprinting of skin disease has the potential to dramatically improve diagnostic sensitivity and open the door for personalised medicine. To date, there have been no reports on biomarker profiling of lesional samples in a prospective study due to the lack of suitable technologies to perform multiple sampling over time. This is due to the iatrogenic issue of cutting out the lesion through biopsy precluding further study of that lesion.

This problem exists in many medical disciplines and has led to the evolution of experimental diagnostic devices towards miniaturised versions of their predecessors. This miniaturisation trend is enabled by several factors including improved micro-manufacturing tolerances, decreasing costs and increasing availability. One of the earliest micro-devices developed to obtain biopsy samples was patented by Krulevitch et al. They patented microbiopsy/precision cutting devices fabricated by conventional machining, silicon micromachining, precision machining and injection moulding. Over the years, there have been many similar patents that report a variety of such microbiopsy devices. The unifying theme is that these patents all describe micro-biopsy devices for breast or intestinal tissue sampling and importantly none were engineered for skin or skin lesions.

Our group has developed a new microbiopsy platform technology that enables the collection of tiny pieces of skin using a micro-medical device that is minimally invasive and does not require local anaesthesia (IP Australia Appl. Num. 2012901490, filed on 16/04/2012). There are situations when conventional biopsies are not appropriate. Skin disease may present with multiple lesions and/or in a cosmetically sensitive area. Certain areas such as the lower leg may have problems with wound healing and so biopsies are avoided. The microbiopsy device fills a void in dermatology where conventional biopsies are not feasible or could do more harm than good. We have observed that microbiopsy sampling does not interfere with downstream histopathological diagnosis. The data presented herein describe the fabrication, optimisation and early steps toward the validation of a novel microbiopsy device for use in vivo.

Materials and methods
Microbiopsy device fabrication
The microbiopsy devices used in our studies were fabricated by laser cutting plates of stainless steel. The in-house fabrication of microbiopsy devices involves laser cutting of two-dimensional designs on 0.05 mm thick medical grade stainless steel (304, Mastercut Technologies, Australia) at 95% power, 30% frequency and speed of 0.9 using a 20 W laser marking system (LaserPro S290, GCC, Taiwan). All of the 2D microbiopsy components were assembled into 3D devices, and sterilized using a glass bead sterilizer.

Figure 1. Size comparison of needle, biopsy devices and biopsy comparisons. A conventional biopsy punch is shown on the left, an 18 gauge syringe needle in the centre and the inner chamber of our microbiopsy device on the right Panel (a). Our microbiopsy device chamber is 0.15 mm in width with an outer width of 0.25 mm. The top row of Panel (b) contains a conventional 3 mm biopsy site and tissue, whereas the bottom panels show microbiopsied skin and tissue.
Microbiopsy device imaging
A bench top scanning electron microscope (SEM) (JCM-6000 Neo-
scope, JEOL, USA) was used to acquire high-resolution images of
the microbiopsy device. The roughness amplitude of the microbi-
opsy chamber was obtained by measuring the average distances of
the edge to a regression-fitted straight line using MatLab (Math-
works, Australia).

Microbiopsy and conventional biopsy sample collection
Microbiopsy samples were either obtained in vivo from healthy vol-
unteers (HREC/12/QPAH/082, Metro South Human Research Ethics
Committee, Centres for Health Research, Princess Alexandra Hospi-
tal) or ex vivo from excised actinic keratosis (AK) lesions. The skin
of a healthy volunteer was swabbed with alcohol and the microbi-
opsy applied. Conventional biopsies e.g. punch (Figure 1b) or shave
biopsies, were performed with informed consent from patients
(HREC/08/QPAH/207 for healthy skin or HREC/11/QPAH/477 for
AK lesions) prior to being microbiopsied. Samples were collect-
ed in sterile RNase and DNase free 1.5 ml microcentrifuge tubes
containing either RNALater® (Life Technologies, USA) or pH 7.0
phosphate buffered saline (PBS) on ice within 20 minutes after tis-
sue removal from patients. All samples placed in RNALater® were
kept overnight at 4°C and then stored at -80°C.

Measurement of pain score
Volunteer pain scores were evaluated with Metro South Human
Research Ethics Committee, Princess Alexandra Hospital approval
(HREC/12/QPAH/082). Each of the 20 volunteers (Table 1) was pre-
sented with an assessment form to grade his/her expected pain score
based on a numerical rating 10-point Likert scale, 0 as having no
pain and 10 as pain as bad as they can imagine before the start of the
experiment. Each microbiopsy application was performed one min-
ute apart and the pain score recorded immediately after application.
Five minutes after the final microbiopsy application, the volunteers
were asked to rate the level of pain for each microbiopsy site.

Reflectance confocal microscopy
Microbiopsy sites were visualized with a reflectance confocal mi-
roscope (RCM, Vivascope 1500® Multilaser, Lucid, Inc., USA) in
volunteers or in excised skin (HREC/12/QPAH/217). RCM was also
used to perform in vivo examination of the skin after microbiopsy.
RCM images were collected through the microscope head, integrat-
ed with a water immersion objective, at a near-infrared wavelength
of 785 nm. Blocks consisting of 7 x 7 mm mosaics of stitched RCM
images and 2 µm to 200 µm vertical z-stacks were acquired at the
microbiopsy sampling site. Dermatoscopic images were collected
with a Canon Power Shot G10 digital camera (Canon, Japan) and a
dermatoscope attachment (DermLite®, 3Gen, USA).

Microbiopsy site visualisation histology
Microbiopsied tissue was embedded (Optimal cutting tempera-
ture compound, Sakura Finetek, USA) and cryosectioned (CM1850,
Leica Microsystems Pty Ltd, Australia). The 10 µm thick sections
were fixed with 100% cold methanol for 10 minutes, air dried and
stained with haematoxylin and eosin (Varistain Gemini ES, Thermo
Fisher Scientific Inc., USA) to visualize the microbiopsy sites.

Nuclear labelling and confocal microscopy
The microbiopsy extracted tissue was incubated with DRAQ5
(BioStatus Limited, UK) at 10 µM in PBS for 30 minutes at room
temperature. Confocal microscopy images were taken with a Zeiss
510 META confocal microscope (Carl Zeiss Microscopy GmbH,
Germany). A 3D projection was then created from the z-stacks
(2 µm steps) of confocal images using Imaris (Bitplane Scientific
Software, Switzerland). ImageJ (NIH, USA) was used to estimate
the nuclei in microbiopsy samples.

DNA isolation
DNA was extracted from the microbiopsy samples using QIAamp
DNA Micro purification kits (QIAGEN GmbH, Germany) using a
protocol modified to accommodate the unique microbiopsy sam-
ple. The microbiopsy was removed from the applicator housing
after application. The presence of a tissue sample was quickly con-
firmed by opening the microbiopsy device and visualizing with a
stereo microscope (Carl Zeiss Microscopy GmbH, Germany). The
opened device was then immersed in 180 µl lysis buffer (Buffer ATL,
QIAGEN GmbH, Germany) in the presence of proteinase K (20 µl)
in a 1.5 ml tube. Fifteen seconds of pulse-vortexing was applied to
ensure that the sample was well-mixed. The sample was then placed
in a thermomixer (Eppendorf, Australia) at 56°C with shaking at 800
rpm overnight. The tube containing the device was briefly cen-
trifuged for 10 seconds to remove the solution adhering to the
cap of the tube before transferring the lysate into a new tube. The
tube containing the device was centrifuged again at 6000 g for
30 seconds to remove any lysate adhering to the device. The lysates
were combined and the remaining procedure followed the manufac-
turer supplied instructions.

RNA isolation
The modified sample lysing processing described in DNA iso-
lation above was also used with the Arcturus® PicoPure® RNA
Isolation Kit (Life Technologies, USA) to obtain total RNA from
microbiopsy samples. RNA isolation of lesional samples was per-
formed using RNeasy Mini Kit (QIAGEN GmbH, Germany) ac-
cording to the RNeasy Mini Handbook (version 2010).

DNA and RNA quantification
A quantitative fluorometer-based assay (Qubit® 2.0, Life Tech-
nologies, USA) was used to determine the concentration of DNA
and RNA with the protocol provided by the manufacturer.
RNA quality control
Agilent RNA 6000 Nano and Pico kits (Agilent Technologies, USA) were used to determine the RNA integrity number (RIN) of lesional and microbiopsy samples after RNA isolation. The supplied protocol was followed.

Whole transcriptome amplification
Identical amounts of total RNA (14 ng) for both lesional and microbiopsy samples were subjected to whole transcriptome amplification. The procedure was carried out using the supplied instructions (QuantiTect Whole Transcriptome Kit, QIAGEN, Australia). The cDNA obtained from the amplification process was used as a template in a polymerase chain reaction (PCR) reaction using human beta actin primers (forward: ATC TGG CAC ACC TTC TAC AAT GA; reverse: CGT CAT ACT CCT GCT TGC TGA TCC AC) (Integrated DNA Technologies, NSW, Australia). There was an initial denaturation for 2 minutes at 98°C, followed by 30 cycles of 98°C for 30s (denaturation), 67°C for 30s (annealing), and 72°C for 1 minute (extension). The cDNA and PCR products were run on a 1% agarose gel (Bio-rad Laboratories, Inc., Australia) and visualized with RedSafe (ChemBio, UK). HyperLadder™ 1 kb (Hyper-Ladder I) (Bioline, UK) was used to determine the mass of cDNA and human beta actin amplicons.

Statistical analysis
Statistical analysis was performed using PRISM 6 for Windows (GraphPad Software, Inc., USA). Channel width, velocity and roughness amplitude data were presented as mean ± SD. Pain score for channel width and velocity were presented as minimum to maximum box-and-whiskers plot. One-way ANOVA combined with a Tukey’s multiple comparison post-test was performed to determine the statistical significance.

Results
Our microbiopsy device has a chamber volumetric size of 0.003 mm³ that is more than 6000 times smaller than a conventional 3 mm punch biopsy and more than 5 times smaller than an 18 GA syringe needle (Figure 1a). Figure 1b demonstrates the size differences between a conventional 3 mm punch biopsy (top panels) and our microbiopsy (bottom panels).

Channel width optimisation
We conducted a volunteer study in 20 healthy individuals to determine the optimal channel width and application velocity for this device. Extracted DNA mass was chosen to be the primary indicator for sample-to-sample comparisons. Interestingly, we observed tissue collection (4.5 ± 1.5 ng DNA) around the rough edges of a microbiopsy device without a chamber (Figure 2a–b, channel width of 0 mm). After applying the microbiopsy, the device was opened up and visualized under a dissecting microscope. Successful collection was achieved when tissue was evident within or around the device and unsuccessful if no tissue was present. Tissue was collected from all volunteers (n=20) when a 0.15 mm channel width microbiopsy device was used. Only 13 successful collections were achieved from 20 applications when a 0.20 mm channel width microbiopsy device was used. This indicated that the collection rate decreased from 100% to 65% when channel width was increased by 0.05 mm. The device without a channel (0 mm channel width) captured tissue around the edges of the tapered plates in all replicates (n=20). This experiment showed that a channel width of 0.15 mm obtained the highest average amount of DNA (5.9 ± 3.4 ng), which was significantly higher than 0.25 and 0.30 mm channel widths (p < 0.0001). There was no significant difference in the total DNA extracted between 0–0.20 mm channel widths (Figure 2a).

Application velocity optimisation
Microbiopsy application velocity was evaluated by using defined applicator springs to achieve velocities between 0–20.2 m/s (Figure 2d). Only negligible amounts of DNA were recovered when the device was applied at less than 9.2 m/s. However, there was a 7.5-fold increase (0.8 ± 0.8 to 6.0 ± 3.0 ng) in DNA recovered when the application velocity was increased from 9.2 m/s to 16.6 m/s (p < 0.0001). An additional increase to 20.2 m/s increase in application velocity did not result in significant increases in DNA collection.

Pain scale assessment
There was no change in the level of pain reported when microbiopsies with varying channel widths were applied (Figure 2e). The level of pain significantly increased and variation increased when microbiopsies were applied at increasing velocities (Figure 2e). All of the volunteers had a pain score of 0 at 5 minutes after the final microbiopsy application (data not shown). The volunteers scored pain between 0 to 10 with an average score of 1.5 ± 1.1, when the 0.15 mm channel width microbiopsy was applied at 20.2 m/s.

Edge roughness optimisation
We observed DNA collection without a centre chamber (Figure 2a, 4.5 ± 1.4 ng from channel width 0 mm) and hypothesized that surface roughness could be key to successful sample collection. We compared microbiopsy devices with varying roughness amplitudes (Rₐ) and observed an increasing trend in total DNA extracted with increasing Rₐ (Figure 3a) (n=20 for 5.36 Rₐ and n=5 for 0.92 and 1.32). The SEM images of the inner chamber edge were used to measure the Rₐ. These measurements ranged from relatively smooth (Rₐ 0.92) to rough (Rₐ 5.36) (Figure 3b, side view).

Microbiopsy sample imaging
RCM was used to visualise the microbiopsy application site. RCM images revealed a microbiopsy site similar to the size of a small hair follicle in the dermal papillary post microbiopsy application (Figure 4a and 4b). The inset shows that microbiopsy application resulted in a puncture site that was approximately 0.10 × 0.50 mm in dimension (Figure 4b). Microbiopsy samples were stained with DRAQ5 (BioStatus Limited, UK) to highlight the nuclei. Confocal images were used to generate a 3D model of the microbiopsy sample. The usual skin strata were apparent in this model. We estimated that there were 1634 nuclei in Figure 4c. We observed 0.22 ± 0.12 mm wide and 0.26 ± 0.09 mm deep puncture sites in excised abdominal skin from 10 histological sections (Figure 4d).

Microbiopsy sample molecular characterisation
One of our goals was to compare AK lesions to microbiopsy samples since many of these lesions can be present in patients but only a few progress to squamous cell carcinoma and the molecular mechanism behind this transition is a focus of intense research. Microbiopsy samples were taken from freshly excised AKs. The RNA from these
Figure 2. Microbiopsy channel width and velocity optimisation. Channel width and velocity were varied to optimise the microbiopsy device configuration. Total DNA was used as a surrogate for sample size. Panel (a) shows the DNA extracted from device with varying channel width and that the maximum amount of DNA was collected with 0.15 mm channel width. Panel (b) displays high resolution scanning electron microscopic images showing different channel widths of the microbiopsy device. Panel (c) shows the level of pain volunteers reported when different channel width microbiopsies were used. Panel (d) shows the varying velocity applied and that the maximum amount of DNA was collected when the device was applied at 16.6 m/s. Panel (e) shows the level of pain volunteers reported when application velocity was varied.
matched samples had comparable quality with an average RIN difference of \(-0.85 \pm 0.85\) for \(n=4\). Representative Bioanalyzer (Agilent Technologies, USA) results for the conventional biopsy (RIN 6.50) and microbiopsy (RIN 5.10) are shown in Figure 5, left panel. The results showed that there are similarities and differences in the RNA bands, which may be due to the large amount of tissue sampled with conventional biopsy and the relatively small number of cells sampled with the microbiopsy.

The small sample size is an inherent limitation of the microbiopsy device. To mitigate this, a pilot experiment was conducted where the microbiopsy sample was subjected to whole transcriptome amplification for RNA analysis. We included a skin sample with the same amount of starting material (14 ng) as an amplification control in the experiment. We observed a 2000-fold increase in cDNA from both samples based on total RNA and cDNA measurements. The cDNAs were of comparable quality and quantity (Figure 5, Transcriptome Amplification to cDNA). Subsequently, we used PCR to amplify human beta-actin mRNA. We observed 2 identical bands at 800 bp with comparable PCR product quality both lanes (Figure 5, Actin PCR).

Wound healing kinetics
Immediately after microbiopsy application we observed local erythema that resolved within 24 hours. The tiny excision site from the microbiopsy healed quickly and was invisible to the naked eye after 24 hours (Figure 6). We used dermoscopy and RCM to monitor the wound healing process at regular intervals (Figure 6, center and right columns).

Influence of channel width and velocity of microbiopsy on DNA, extraction, RNA extraction and pain scores in volunteers

Discussion and conclusion
In this proof of concept study, we have shown that an arrangement of stacked plates to form a 3D microbiopsy device is capable of providing molecular samples from normal and diseased skin. DNA extraction from human skin is critical for stratifying lesions in terms of mutational status. This type of characterization is becoming more and more relevant as targeted signalling inhibitors are being added to the therapeutic arsenal. Recent developments in molecular inhibitors for skin cancer, e.g. Vemurafenib\(^\text{13}\) and Trametinib\(^\text{14,15}\), are driving a new need for molecular diagnostic information that cannot be gathered through morphologic analysis. Molecular biomarkers have been used to detect cancer, but are now being developed to determine which molecular therapeutic will be the most effective. Melanoma clinical biology research has resulted in genomic data identifying oncogenes that can be targeted by protein kinase inhibitors e.g. BRAFT\(^\text{16}\) and MEK\(^\text{16}\). Diagnostic assays to detect BRAFT and NRAS mutations are now being used to stratify skin cancer lesions\(^\text{17}\). The microbiopsy device has the potential to help screen multiple lesions for specific mutations, and to be important in discovery based research.

Yancovitz et al. describe intra- and inter-tumour heterogeneity of melanoma in the context of BRAFT\(^{V600E}\) mutations\(^\text{18}\). Hematoxylin
Figure 4. **Site of microbiopsy and microbiopsy content.** Panels (a) and (b) are reflectance confocal microscopy mosaics of a microbiopsy site, see the hair follicles featured in the centre and on the right hand side of the images for size comparison (bar indicates 0.5 mm in a and b). Panel (c) shows a 63x magnification, 3D rendering of the microbiopsy tissue with a nuclear counter stain (orange) derived from a confocal microscopy z-stack of the sample within the microbiopsy device. The stratum corneum (SC), viable epidermis (VE), dermal-epidermal junction (DEJ) and superficial dermis (DER) are labeled. This microbiopsy contained an estimated 1634 nuclei. Haematoxylin and eosin stained section of human skin after microbiopsy application shows a 0.10 mm wide and 0.25 mm deep puncture Panel (d). * indicates the site of microbiopsy application.

Figure 5. **Molecular characterization of conventional shave biopsies and microbiopsies.** The left panel shows the Bioanalyzer readout from RNA isolated from a conventional actinic keratosis (AK) shave biopsy next to microbiopsy obtained RNA from the same AK lesion. The right panel compares the RNA quality of a shave biopsy and normal skin microbiopsy that were subjected to total transcriptome amplification to generate cDNA. The cDNA was then used as a template for a PCR reaction containing actin specific primers with an expected product at 800 bp.
and eosin stained sections of primary and metastatic lesions were subjected to laser capture microdissection to isolate the lesions of interest. They captured 30–300 cells for each lesion of interest. This is less than 5 times that captured with the microbiopsy device. The authors used the same DNA extraction kit as we did to isolate lesional DNA for analysis. These samples were then used to detect \(BRAF^{V600E}\) tumour heterogeneity. Based on our analysis, we estimate that Yancovitz et al. isolated <1 ng of DNA in this study and were able to amplify \(BRAF\) exon 15 using conventional PCR followed by mutation analysis. We found that we can reproducibly isolate 5 ng of DNA from the superficial skin and in another publication show the use of the microbiopsy device in dysplastic nevi\(^{11}\).

This work sets the stage for future microbiopsy studies focused on \(BRAF\) mutational analysis in nevi \(in\) \(situ\). The addition of RNA analysis to mutational studies would give additional insights into gene expression profiles of these lesions.

Berglund et al. (2007) reported that their optimised methodology yielded an average 1.4 ± 0.4 µg of consistently high quality RNA (8.4–8.9 RIN) from 3 mm skin punch biopsies\(^{19}\). Another group reported that they had isolated an average of 1.5 µg of RNA with an average RIN value of 8.1 from half of a 4 mm punch biopsy skin sample (\(n=97\))\(^{20}\). The average total RNA yielded from the microbiopsy device is 9.0 ± 10.1 ng (\(n=5\)). Even though we isolated far less RNA with the microbiopsy device, our proof of concept study supports the hypothesis that this limitation can be addressed using commercial amplification kits and PCR (Figure 5) for investigating the molecular basis of skin disease.

Discovering non-melanoma skin cancer biomarkers and potential therapeutic targets is an emerging area of research. For example, Dang et al. (2006) focused on the genetic changes that occur in AK to squamous cell carcinoma (SCC) for prospective development of new diagnostic tools and therapeutic approaches. They reported that 7 out of 14 genes in 10 AK, 10 SCC and 20 normal skin samples related to cell adhesion, communication, metabolism and respiration were significantly dysregulated in AK and SCC (\(p < 0.05\))\(^{21}\). The microbiopsy device has the potential to help facilitate longitudinal studies within a single lesion.

Application of the relatively small microbiopsy device does not require local anaesthesia or sutures and therefore no set up for a minor clinical procedure is necessary. Observations from our volunteer study suggest that collecting multiple microbiopsies within a short period is feasible. We envision that microbiopsy devices will become a routine clinical and research device in dermatology allowing the dermatologist to obtain targeted lesion data for molecular stratification.

**Consent**

Written informed consent for publication of their clinical images was obtained from the patients (HREC/11/QPAH/477 and/or HREC/12/QPAH/082, Metro South Human Research Ethics Committee, Centres for Health Research, Princess Alexandra Hospital).

**Figure 6.** Wound healing kinetics of microbiopsy site. The left column shows dermoscopic images of the microbiopsy site over time. The middle and right column are mosaics and at 30x magnification reflectance confocal microscopy (RCM) images, respectively, of the microbiopsy site.

**Author contributions**

LLL, HPS and TWP contributed to the experimental design and preparation of the manuscript. LLL, APR, CAP, RLH and ABA carried out the research. APR contributed to the design of experiments. All authors were involved in the revision of the draft manuscript and have agreed to the final content.

**Competing interests**

No competing interests were disclosed.
Grant information
This project was supported by Epiderm (Boronia Park, NSW 2111, Australia) and NHMRC Practitioner Fellowship (APP1020148) (HPS).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We thank Drs. Sudipta Sinnya and Jean-Marie Tan for patient recruitment and clinical assistance. We thank Dr. Roy Hall for providing the human actin primers and Dr. Yin Xiang Setoh for assisting in the PCR experiment. We thank Dr. Rick Sturm for his valuable input on the molecular characterization of this device.

References

1. Sina B, Kao GF, Deng AC, et al.: Skin biopsy for inflammatory and common neoplastic skin diseases: optimum time, best location and preferred techniques. A critical review. J Cutan Pathol. 2009; 36(5): 505–510. PubMed Abstract | Publisher Full Text
2. Pickett H: Shave and punch biopsy for skin lesions. Am Fam Physician. 2011; 84(9): 995–1002. PubMed Abstract
3. Ugurel S, Utikal J, Becker JC: Tumor biomarkers in melanoma. Cancer Control. 2009; 16(3): 219–224. PubMed Abstract
4. Shivers S, Jakub J, Pendas S, et al.: Molecular staging for patients with malignant melanoma. Expert Rev Anticancer Ther. 2007; 7(11): 1665–1674. PubMed Abstract | Publisher Full Text
5. Groenert R: Skin cancer: new markers for better prevention. Pathobiology. 2009; 76(2): 64–81. PubMed Abstract | Publisher Full Text
6. Kroulitch PA, Lee AF, Northrup MA, et al.: Microbiopsy/Precision cutting devices. In: Edited by Patent US. United States: The Regents of the University of California; 1999. Reference Source
7. Byun S, Lim JM, Paik SJ, et al.: Barbed micro-spikes for micro-scale biopsy. J Micromech Microeng. 2005; 15(6): 1279–1284. Publisher Full Text
8. Cho D, Park SK, Lee AR, et al.: Catheter capable of being equipped with micro biopsy tool. In: Edited by Patent US; 2011. Reference Source
9. Cosnier ML, Martin F, Bouamanni A, et al.: A minimally invasive microdevice for molecular sampling and analysis. IEEE Trans Biomed Eng. 2009; 56(12): 2898–2904. PubMed Abstract | Publisher Full Text
10. Pfliuger DR: Micro-invasive breast biopsy device. In: Edited by Patent US; 2004. Reference Source
11. Banan P, Lin LL, Lambie D, et al.: Effects of Ex Vivo Skin Microbiopsy on histopathological diagnosis in melanocytic skin lesions. JAMA Dermatol. 2013; 149(9): 1107–9. PubMed Abstract | Publisher Full Text
12. Fuch A, Marmur E: The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg. 2007; 33(9): 1099–1101. PubMed Abstract | Publisher Full Text
13. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507–2516. PubMed Abstract | Publisher Full Text | Free Full Text
14. Flaherty KT, Infante JR, Daud A, et al.: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2011; 367(18): 1694–1703. PubMed Abstract | Publisher Full Text | Free Full Text
15. Flaherty KT, Robert C, Hersey P, et al.: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107–114. PubMed Abstract | Publisher Full Text
16. Romano E, Schwartz GK, Chapman PB, et al.: Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011; 12(6): 913–922. PubMed Abstract | Publisher Full Text
17. Jin SA, Chun SM, Choi YD, et al.: BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas. J Invest Dermatol. 2013; 133(2): 579–582. PubMed Abstract | Publisher Full Text
18. Yancovitz M, Literman A, Yoon J, et al.: Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS One. 2012; 7(1): e29336. PubMed Abstract | Publisher Full Text | Free Full Text
19. Berglund SR, Schwiertzen CW, Jones AA, et al.: Optimized methodology for sequential extraction of RNA and protein from small human skin biopsies. J Invest Dermatol. 2007; 127(2): 349–353. PubMed Abstract | Publisher Full Text
20. Broning O, Rodenburg W, Radonic T, et al.: RNA isolation for transcriptomics of human and mouse small skin biopsies. BMC Res Notes. 2011; 4: 438. PubMed Abstract | Publisher Full Text | Free Full Text
21. Dang C, Gottschling M, Manning K, et al.: Identification of dysregulated genes in cutaneous squamous cell carcinoma. Oncol Rep. 2006; 16(3): 513–519. PubMed Abstract
22. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol. 1988; 124(6): 869–871. PubMed Abstract | Publisher Full Text

Page 10 of 15
This is an interesting study, describing the development and characterisation of a device to take small biopsies from skin lesions. Attractively, it appears to allow for sampling of tissue with minimal discomfort. The extracted sample can be processed through DNA and RNA extraction protocols. The authors describe how this device may influence future changes in molecular diagnostics in skin tumours.

The paper is well written. There are a few minor revisions that should be made for it to be acceptable for indexing.

- **Title and Abstract:**
The word painless in the second line should be removed as this is not substantiated by the data provided. The volunteers expressed that pain was experienced at the time of the biopsy, indicated in the score in Table 1.

- **Article content:**
*Improved wound healing at high risk sites*
Page 3 of 11 – “Certain areas such as the lower leg may have problems with wound healing and so biopsies are avoided. The microbiopsy device fills a void in dermatology where conventional biopsies are not feasible or could do more harm than good.” – This needs to be substantiated by data showing that the device resulted in fewer lower leg complications for this statement to stand. Otherwise it should be removed.

*Comparison to 4mm punch biopsies*
The disadvantages of the punch biopsy approach (anaesthesia, suturing) are highlighted. Whilst the thrust of the article is the extraction of tissue for molecular analysis at a nucleic acid level, for a balanced view, it should be pointed out that punch biopsies allow for histological assessment of the tissue sampled, whilst the microbiopsy device does not. It may also be worth considering future studies where pain scores are assessed in patients who volunteer to have both a punch biopsy and a microbiopsy undertaken, to compare the difference.
between the 2 approaches.

**RNA quality**
It has to be acknowledged that whilst the RNA extracted was amplified to cDNA, the starting RNA integrity number of the sample published (5.5) would not be considered suitable for whole transcriptome approaches, such as RNA-seq and microarray profiling, where ideally a RIN of >8 is desirable.

**DNA quality**
It would be good to see an indication of the DNA quality and integrity from tissue extracted with this device, using either a bioanalyzer approach or an agarose gel.

- **Conclusions:**
The conclusions are sensible, balanced and justified on the basis of the results of the study.

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The title and abstract, article content, conclusions and data are all highly appropriate. I am particularly impressed with the ability to obtain intact DNA and RNA from this technique. Given the almost total lack of scarring, I predict that this method will be highly used and this paper will be highly cited in the field. I look forward to utilizing it in my own practice. The ease of wound healing makes it particularly attractive

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

---

**Comments on this article**

**Version 1**

Author Response 04 Jul 2013

Tarl Prow, The University of Queensland, School of Medicine, Translational Research Institute, Brisbane, Australia

We thank the reviewers for their time and comments.

Reviewer #3 (Neil Rajan)

1. **The word painless in the second line should be removed as this is not substantiated by the data provided.** Response: We will replace ‘painless’ to ‘minimally invasive’ in line 2 of the abstract.

2. Page 3 of 11 – “Certain areas such as the lower leg may have problems with wound healing and so biopsies are avoided. The microbiopsy device fills a void in dermatology where conventional biopsies are not feasible or could do more harm than good.” – This needs to be substantiated by data showing that the device resulted in fewer lower leg complications for this statement to stand. Otherwise it should be removed. Response: We will remove the sentence “Certain areas such as the lower leg may have problems with wound healing and so biopsies are avoided.” and rephrase the following sentence “The microbiopsy device fills a void in dermatology where conventional biopsies are not feasible or could do more harm than good” to “The microbiopsy device has the potential to fill a void in dermatology where conventional biopsies are not feasible or could do more harm than good”.

3. The disadvantages of the punch biopsy approach (anaesthesia, suturing) are highlighted.
Whilst the thrust of the article is the extraction of tissue for molecular analysis at a nucleic acid level, for a balanced view, it should be pointed out that punch biopsies allow for histological assessment of the tissue sampled, whilst the microbiopsy device does not. It may also be worth considering future studies where pain scores are assessed in patients who volunteer to have both a punch biopsy and a microbiopsy undertaken, to compare the difference between the 2 approaches. Response: This is a very relevant statement. We will include the following sentence in line 1, first paragraph of discussion, “Whereas conventional biopsies allow accurate diagnosis of tissue sampled through histopathological assessment, there is a need for an alternative technology, such as the microbiopsy, to screen multiple lesions through molecular diagnosis.” Your suggestion of assessing pain level from both punch biopsy and microbiopsy in volunteers is valuable and we will include this in our future study directions in the discussion and conclusion section.

4. It has to be acknowledged that whilst the RNA extracted was amplified to cDNA, the starting RNA integrity number of the sample published (5.5) would not be considered suitable for whole transcriptome approaches, such as RNA -seq and microarray profiling, where ideally a RIN of >8 is desirable. Response: Thank you for highlighting this important point. We will include the following sentence in line 12, third paragraph of discussion, “Through the course of these experiments we observed RNA integrity values that ranged between 1.2 and 7.6 with the microbiopsy. We also observed that these values correlated with matched conventional shave biopsies. In some cases the values were quite low (e.g. RIN 5.1 in Figure 5) and would not be considered for whole transcriptome approaches. Sampling for RNA analysis can be difficult and optimizing this application for the microbiopsy is one of our priorities as we move forward with this technology.”

5. It would be good to see an indication of the DNA quality and integrity from tissue extracted with this device, using either a bioanalyzer approach or an agarose gel. Response: We are in the process of preparing an additional manuscript where we compare the mutational profiles of matched microbiopsies and conventional biopsies from lesional samples, including the DNA quality and integrity of these samples. So far, our bioanalyzer data shows that the DNA is intact, without signs of degradation and the mutational analysis has been successful. These observations strongly support the hypothesis that the DNA sampled is intact. We will revise Figure 5 to include a Bioanalyzer DNA readout to show the quality and integrity of amplified DNA that were extracted from a microbiopsy sample and matched conventional shave biopsy sample.

**Competing Interests:** No competing interests were disclosed.
The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com